Skip to content

Study · Not a test of the peptide alone · 2021

4 results

SL010110, a lead compound, inhibits gluconeogenesis via SIRT2-p300-mediated PEPCK1 degradation and improves glucose homeostasis in diabetic mice.

Ren YR, Ye YL, Feng Y, Xu TF, Shen Y, Liu J, Huang SL, Shen JH, Leng Y

Acta pharmacologica Sinica11 Feb 2021Cited by 15 (Europe PMC)

PMID33574568 (opens in a new tab)PMCIDPMC8563938 (opens in a new tab)DOI10.1038/s41401-020-00609-w (opens in a new tab)PepBankPUB-33574568
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, NMN (nicotinamide mononucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking NMN (nicotinamide mononucleotide).

  1. 01LabNot a test of NMN (nicotinamide mononucleotide) aloneIn vitro (cells)Mechanism

    In primary mouse hepatocytes, NMN blocked the SL010110-induced decrease in NAD+/NADH ratio.

    In plain wordsIn cells from mouse liver, NMN blocked the decrease in NAD+/NADH ratio caused by SL010110.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseNAD+/NADH ratio rescue
    Study

    mousen: not reported in source

    Primary mouse hepatocytes exposed to SL010110
    Outcome group
    Receptor activity and mechanism · Liver

    Source sentences

    Summary
    These effects were blocked by NMN, an NAD+ precursor, suggested that SL010110 inhibited gluconeogenesis by inhibiting SIRT2, activating p300, and subsequently promoting PEPCK1 acetylation.
    2 context sentences
    Summary · context
    SL010110 decreased NAD+/NADH ratio, inhibited SIRT2 activity, and further promoted p300 acetyltransferase activation and PEPCK1 acetylation.
    Summary · context
    SL010110 activated p300 acetyltransferase activity in primary mouse hepatocytes.

    In this study, NMN (nicotinamide mononucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NMN (nicotinamide mononucleotide).

  2. 02LabNot a test of NMN (nicotinamide mononucleotide) aloneIn vitro (cells)Mechanism

    In primary mouse hepatocytes, NMN blocked SL010110-induced inhibition of SIRT2 activity.

    In plain wordsIn cells from mouse liver, NMN blocked SIRT2 activity inhibition caused by SL010110.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseSIRT2 activity rescue
    Study

    mousen: not reported in source

    Primary mouse hepatocytes exposed to SL010110
    Outcome group
    Receptor activity and mechanism · Liver

    Source sentences

    Summary
    These effects were blocked by NMN, an NAD+ precursor, suggested that SL010110 inhibited gluconeogenesis by inhibiting SIRT2, activating p300, and subsequently promoting PEPCK1 acetylation.
    2 context sentences
    Summary · context
    SL010110 decreased NAD+/NADH ratio, inhibited SIRT2 activity, and further promoted p300 acetyltransferase activation and PEPCK1 acetylation.
    Summary · context
    SL010110 activated p300 acetyltransferase activity in primary mouse hepatocytes.

    In this study, NMN (nicotinamide mononucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NMN (nicotinamide mononucleotide).

  3. 03LabNot a test of NMN (nicotinamide mononucleotide) aloneIn vitro (cells)Mechanism

    In primary mouse hepatocytes, NMN blocked SL010110-induced p300 acetyltransferase activation.

    In plain wordsIn cells from mouse liver, NMN blocked p300 activation caused by SL010110.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    Decreasep300 activation blockade
    Study

    mousen: not reported in source

    Primary mouse hepatocytes exposed to SL010110
    Outcome group
    Receptor activity and mechanism · Liver

    Source sentences

    Summary
    These effects were blocked by NMN, an NAD+ precursor, suggested that SL010110 inhibited gluconeogenesis by inhibiting SIRT2, activating p300, and subsequently promoting PEPCK1 acetylation.
    2 context sentences
    Summary · context
    SL010110 decreased NAD+/NADH ratio, inhibited SIRT2 activity, and further promoted p300 acetyltransferase activation and PEPCK1 acetylation.
    Summary · context
    SL010110 activated p300 acetyltransferase activity in primary mouse hepatocytes.

    In this study, NMN (nicotinamide mononucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NMN (nicotinamide mononucleotide).

  4. 04LabNot a test of NMN (nicotinamide mononucleotide) aloneIn vitro (cells)Mechanism

    In primary mouse hepatocytes, NMN blocked SL010110-induced PEPCK1 acetylation.

    In plain wordsIn cells from mouse liver, NMN blocked PEPCK1 acetylation caused by SL010110.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    DecreasePEPCK1 acetylation blockade
    Study

    mousen: not reported in source

    Primary mouse hepatocytes exposed to SL010110
    Outcome group
    Receptor activity and mechanism · Liver

    Source sentences

    Summary
    These effects were blocked by NMN, an NAD+ precursor, suggested that SL010110 inhibited gluconeogenesis by inhibiting SIRT2, activating p300, and subsequently promoting PEPCK1 acetylation.
    2 context sentences
    Summary · context
    SL010110 decreased NAD+/NADH ratio, inhibited SIRT2 activity, and further promoted p300 acetyltransferase activation and PEPCK1 acetylation.
    Summary · context
    SL010110 activated p300 acetyltransferase activity in primary mouse hepatocytes.

    In this study, NMN (nicotinamide mononucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NMN (nicotinamide mononucleotide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.